On May 16, 2018 Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) Shorts Rose By 7.7%

May 16, 2018 - By Sheila Anderson

Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) had an increase of its short interest by 7.7%. In May was published AQXP’s total 265,700 short interest by FINRA. The 246,700 previous shares are up with 7.7%. 5 days will cost AQXP with 57,000 average volume to restore its former position. Float short on Aquinox Pharmaceuticals Inc is 2.13%.

AQXP is reaching $13.25 during the last trading session, after increased 3.52%.Aquinox Pharmaceuticals, Inc. has 182,963 shares volume, 111.06% up from normal. AQXP is downtrending and has moved 8.81% since May 16, 2017. AQXP underperformed the S&P500 by 20.36%.

Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology.The company has $311.27 million market cap. The firm primarily focuses on anti-inflammatory product candidates targeting SH2-containing inositol-5Â’-phosphatase 1 enzyme, a key regulator of a cellular signaling pathway in immune cells.Currently it has negative earnings. The Company’s lead product candidate is AQX-1125, a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome, a chronic inflammatory disease of the bladder.

Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Ratings Coverage

In total 3 analysts cover Aquinox Pharmaceuticals (NASDAQ:AQXP). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 9 are the (NASDAQ:AQXP)’s analyst reports since November 20, 2017 according to StockzIntelligence Inc. On Monday, December 11 the rating was maintained by Canaccord Genuity with “Buy”. On Tuesday, May 8 the stock of Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) has “Buy” rating given by Cantor Fitzgerald. The stock rating was maintained by Canaccord Genuity with “Buy” on Monday, March 12. On Monday, November 20 the stock of Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) has “Buy” rating given by Canaccord Genuity. On Monday, March 12 Cantor Fitzgerald maintained Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) with “Buy” rating. On Sunday, February 11 the company was maintained by Cantor Fitzgerald. On Monday, May 14 the company was maintained by Canaccord Genuity. On Tuesday, December 19 the rating was maintained by Canaccord Genuity with “Buy”.

For more Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) news posted recently go to: Globenewswire.com, Globenewswire.com, Globenewswire.com, Globenewswire.com or Nasdaq.com. The titles are as follows: “Aquinox and Astellas Announce Exclusive Licensing Agreement for Rosiptor in the Asia-Pacific Region Including Japan” posted on May 10, 2018, “Aquinox to Present at Deutsche Bank 43rd Annual Healthcare Conference” on May 02, 2018, “Aquinox to Present at 2018 UBS Global Healthcare Conference” with a publish date: May 16, 2018, “Aquinox Pharmaceuticals Announces First Quarter 2018 Financial Results” and the last “Aquinox to Present at 2018 Bloom Burton & Co. Healthcare Conference” with publication date: April 26, 2018.

Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: